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Abstract
Background: Sarcopenia can contribute to negative outcomes in patients with various lung diseases. However,
whether sarcopenia affects prognosis in patients with idiopathic pulmonary fibrosis (IPF) has not been reported. Simple
measures of muscle mass, derived from chest computed tomography (CT), are increasingly being used to identify
patients with sarcopenia. We hypothesized that skeletal muscle mass could be a predictor of prognosis in IPF patients.
Methods: We retrospectively evaluated 180 patients diagnosed with IPF between January 2010 and December 2015 at
a tertiary care hospital in South Korea. We measured thoracic muscle volume by using the cross-sectional area (CSA) of
the pectoralis, paraspinal, serratus, and latissimus muscles at the 4th vertebral region (T4CSA) and the erector spinae
muscle (ESMCSA) at the 12th vertebral region. CT scans at the time of diagnosis were used for analysis and respective
CSA were divided by height squared to normalize for stature. Survival times were estimated with the Kaplan–Meier
method and compared with the log-rank test. Multivariate Cox proportional hazards models were performed to
investigate relationships between clinical parameters and mortality.
Results: Male patients in the lowest quartile of T4CSA divided by height squared (m
2) (T4MI) and in the lowest quartile
of ESMCSA divided by height squared (m
2) (T12MI) were more likely to have higher Gender-Age-Physiology Index
scores (T4MI, 3.3 ± 1.3 vs 4.0 ± 1.6, P = 0.012; T12MI, 3.2 ± 1.3 vs 4.1 ± 1.6, P = 0.002). Male patients in the lowest quartile
of T4MI exhibited a significantly lower survival rate (P = 0.035). After multivariate Cox proportional hazards analysis, T4MI
was a significant risk factor for all-cause mortality (HR, 0.955; 95% CI, 0.913–0.998; P = 0.041), whereas T12MI was not
(HR, 0.980; 95% CI, 0.856–1.121; P = 0.766).
Conclusions: Low skeletal mass normalized for stature at the level of 4th vertebrae which can be acquired by
quantifying thoracic skeletal muscle on single-slice axial chest CT, may be a strong risk factor for all-cause mortality in
patients with IPF.
Trial registration: The research protocol was approved by the Institutional Review Board of Severance Hospital, South
Korea (IRB No.4–2018-0454).
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Introduction
Sarcopenia is the progressive loss of muscle mass and
strength, which is associated with a risk of adverse out-
comes, such as disability, poor quality of life, and death
[1]. Sarcopenia can cause negative outcomes in patients
with various lung diseases, as well as non-lung diseases,
such as cholangiocarcinoma and breast cancer [2–7].
Idiopathic pulmonary fibrosis (IPF) is a specific form of
chronic, progressive, fibrosing interstitial pneumonia of
unknown cause; it occurs primarily in adults and is
limited to the lungs [8]. Indexes of IPF prognosis
include symptoms, respiratory function, and imaging,
which are important to consider in the clinical progres-
sion of IPF [8]. However, the effect of sarcopenia on
prognosis in patients with IPF has not been reported.
Several modalities have been used to assess sarcope-
nia. Bioelectrical impedance analysis, dual energy
X-ray absorptiometry, magnetic resonance imaging,
and B-mode ultrasound are widely used to quantify
both total and local skeletal muscle mass [1]. Meas-
urement of the cross-sectional area (CSA) of skeletal
muscles on single-slice axial computed tomography
(CT) scans is an alternative method to assess local
skeletal muscle mass [9]. Simple measures of muscle
mass, derived from CT of the abdominal region, are in-
creasingly used to identify patients with sarcopenia [3, 6,
10, 11]. A limitation of this method for evaluating muscle
CSA in chronic respiratory disease is that abdominal CT
scans are not typically performed in clinical respiratory as-
sessment. However, correlations have been found between
muscle CSA at a single thoracic level on chest CT and
total muscle volume in patients with advanced lung dis-
ease [12–14].
Rozenberg et al. observed that, at the level of car-
ina, which corresponds to the 4th vertebral region,
the CSA of the pectoralis, intercostalis, paraspinals,
serratus, and latissimus muscles was associated with
frailty markers, such as 6-min walk distance, biceps
training volume, quadriceps training volume, and
length of hospital stay in lung transplant patients
[15]. Zuckerman et al. reported similar observations
regarding the CSA at the 4th vertebral region, which
was associated with frailty markers [7]. Fuseya et al.
observed that, at the lower margin of the 12th verte-
bral region, CSA of erector spinae muscle (ESMCSA),
a major antigravity muscle group, was associated with
severe airflow limitation, respiratory symptoms, em-
physema severity, and mortality in chronic obstructive
lung disease patients [12].
In this study, we focused on pectoralis, paraspinals,
serratus, and latissimus muscles at the 4th vertebral
region and erector spinae muscle at the 12th vertebral
region. We hypothesized that skeletal muscle mass,
measured by analyzing muscle CSA from chest CT
images at the 4th and 12th vertebral regions, could
be a predictor of prognosis in IPF patients.
Fig. 1 Flow diagram of subjects in this study. Abbreviations; IPF, Idiopathic pulmonary fibrosis; ILD, Interstitial lung disease
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Materials and methods
General methods
We retrospectively reviewed medical records of patients
who were diagnosed with IPF between January 2010 and
December 2015 at one tertiary care hospital in South
Korea. IPF was diagnosed according to an official ATS/
ERS/JRS/ALAT statement [16]. Diagnosis was confirmed
by a multi-disciplinary team consisting of specialists in
pulmonary medicine, radiology, and pathology.
The flow diagram depicting the selection process of
subjects in this study is shown in Fig. 1. Initially, 332
patients who were diagnosed with IPF were included in
the study, selected from our institutional database based
on the following criteria: (1) Patients with confirmed IPF
by either clinical findings or biopsy; (2) CT scan images
at the time of diagnosis were saved in our institutional
radiology database; (3) clinical data were available from
the medical records. Subsequently, patients who under-
went lung transplantation (n = 43), and patients who
were lost to follow-up (n = 109) were excluded. Finally,
180 subjects (143 men and 37 women) were included in
the analysis.
Age, smoking history, pulmonary function test results,
underlying diseases including diabetes, height, weight at
the time of the diagnosis, Gender-Age-Physiology (GAP)
Index [17], usage of drugs that may affect skeletal
muscle mass [18] (statins, sulfonylureas, glinides) and
mortality data were collected for all patients; data
regarding thoracic muscle cross-sectional area (CSA) at
the level of the 4th thoracic vertebra were available in all
patients; data regarding erector spinae muscle CSA at
the level of the 12th thoracic vertebra were available in 174
patients. Computed tomography scan images at the time of
diagnosis were used for analysis. Follow-up data, including
mortality data, were collected until December 2017.
The exact definition of and standardized measurement
techniques for sarcopenia have not yet been established
at the level of T4 or T12 in IPF patients. Therefore,
additional predictor variables were determined based on
studies performed by Rozenberg et al. [15] and Fuseya et
al. [12] We measured sarcopenia indirectly with thoracic
muscle (e.g. pectoralis, intercostalis, paraspinals, serratus,
latissimus muscles) CSA, measured at T4 (T4CSA). We di-
vided the cross-sectional area of skeletal muscle (cm2) at
the T4 level by height squared (m2) to yield the muscle
index at T4 (T4MI, cm2/m2), normalized for stature. We
also sought to measure sarcopenia indirectly with the CSA
of the ESM at the T12 level. We divided the CSA of ESM
(ESMCSA, cm
2) at the T12 level by height squared (m2) to
yield the muscle index at T12 (T12MI, cm2/m2), normal-
ized for stature. The primary outcomes were overall sur-
vival, 1-year survival, and 2-year survival after diagnosis.
Overall survival was estimated from the date of baseline
CT to death or the last follow-up.
Measurement of skeletal muscle CSA at the level of T4, T12
Chest CT examinations were obtained by 16-detector
CT scanners (Somatom Emotion 16; Siemens Health-
care, Erlangen, Germany). Non-contrast CTs were used
in the analysis. Quantitative assessment of the CSA was
performed semi-automatically with Aquarius iNtuition
Viewer (ver. 4.4.11, TeraRecon Inc., San Mateo, CA,
USA) as shown in Fig. 2. T4 was defined as the slice in-
cluding the middle of 4th thoracic vertebrae, and T12
was defined as the slice including the middle of 12th
thoracic vertebrae; the observer visually identified single
cross-sectional images at the levels of T4 and T12,
Fig. 2 a, b: Sample computed tomography (CT) scans used to
determine muscle area in idiopathic pulmonary fibrosis case
subjects. Chest CT examinations were obtained by using 24-detector
CT scanners (Somatom Emotion 16; Siemens Healthcare, Erlangen,
Germany). Non-contrast CTs were used in the analysis. Quantitative
assessment of the CSA was performed semi-automatically with
Aquarius iNtuition Viewer (ver. 4.4.11, TeraRecon Inc., San Mateo, CA,
USA) (a) Axial CT image of the 4th thoracic vertebral region.
Pectoralis, intercostalis, paraspinals, serratus, and latissimus muscles
are in blue. b Axial CT image of the 12th thoracic vertebral region.
Erector spinae muscles are in blue
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respectively. At the T4 level, we then outlined the bor-
ders of the thoracic and back muscles. At the T12 level,
we outlined the borders of the ESM. Tissue CSAs in
slices were computed automatically by summation of the
pixel attenuation of − 30 to + 150 Hounsfield units for
skeletal muscle. After applying the threshold method
(with a predefined Hounsfield unit threshold) to slices,
boundaries between different tissues were corrected
manually when necessary. After measuring CSAs, re-
spective CSA was divided by height square to normalize
for stature, as used in previous studies. A radiology tech-
nician performed measurement of the CSA without ac-
cess to patient information.
Statistical methods
Descriptive statistics are reported as numbers with
proportions or means with standard deviations (SDs).
The continuous variables were tested for normality by
using the Kolmogorov-Smirnov test. Chi-squared tests
or Fisher’s exact tests were conducted to compare
categorical variables between the male and female
groups, sarcopenia and normal groups; Student’s t-tests
or Mann-Whitney tests were conducted to compare
continuous variables between the two groups. Survival
times were estimated with the Kaplan–Meier method
and compared with the log-rank test. Multivariate Cox
proportional hazards models were performed to investi-
gate relationships between clinical parameters and
mortality. Variables with a P-value of < 0.15 by the
log-rank test were included; variables that overlap (e.g.,
age, gender, forced vital capacity (FVC), and diffusing
capacity of carbon monoxide (DLCO) in GAP index)
were excluded. An adjusted P-value < 0.05 was con-
sidered statistically significant. All statistical analyses
were performed with SPSS version 20.0 (SPSS Inc.,
Chicago, IL, USA).
Table 1 Patient characteristics
Variable Total Men Women P-value
Number of patients, n 180 143 (79.4%) 37 (20.6%)
Age, years 69.1 (44–94) 68.7 (44–89) 70.0 (52–94) 0.214
Height, meters, m 1.6 ± 0.1 (1.4–1.8) 1.7 ± 0.1 (1.5–1.8) 1.5 ± 0.1 (1.4–1.7) < 0.001
Weight, kg 63.9 ± 10.3 (33.1–97.3) 65.7 ± 10.2 (33.1–97.3) 56.9 ± 7.1 (46.0–73.0) < 0.001
BMI, kg/m2 23.9 ± 3.2 (12.2–34.9) 23.8 ± 3.3 (12.2–34.9) 24.0 ± 3.2 (17.6–29.6) 0.794
Ever smoker, % 129 (71.6%) 126 (88.1%) 3 (8.1%) < 0.001
Smoking history, pack-years 31.0 ± 23.3 (0–150) 31.5 ± 23.3 (0–150) 8.3 ± 7.6 (0–15) 0.088
Diabetes, n 59 (32.8%) 47 (32.9%) 12 (32.4%) 1.000
Use of Statins or Sulfonylureas or Glinides, n 66 (36.7%) 52 (37.1%) 13 (35.1%) 1.000
FVC, L 2.6 ± 0.8 (0.9–4.8) 2.8 ± 0.8 (0.9–4.8) 1.8 ± 0.5 (0.9–2.8) < 0.001
FVC, % predicted 76.3 ± 17.1 (31–110) 77.1 ± 17.1 (31–110) 72.8 ± 16.6 (34–106) 0.185
FEV1, L 2.1 ± 0.6 (0.8–3.9) 2.2 ± 0.6 (0.8–3.9) 1.3 ± 0.4 (0.8–2.3) < 0.001
FEV1, % predicted 89.0 ± 18.6 (34–128) 89.3 ± 18.9 (34–128) 88.2 ± 17.7 (45–119) 0.753
FEV1/FVC, % 81.44 ± 8.97 (31–100) 80.53 ± 9.07 (31–100) 85.15 ± 7.60 (70–98) 0.007
TLC, L 4.73 ± 1.42 (1.91–8.40) 5.03 ± 1.31 (2.55–8.40) 3.10 ± 0.70 (1.91–4.70) < 0.001
DLCO, ml/min/mm Hg 12.2 ± 5.2 (2.9–46.5) 12.8 ± 5.3 (2.9–46.5) 9.9 ± 3.7 (4.2–17.3) 0.005
DLCO, % predicted 69.6 ± 23.1 (20–149) 71.6 ± 23.3 (20–149) 61.1 ± 20.6 (25–102) 0.025
T4 level muscle CSA, cm2 96.0 ± 25.6 (36.8–163.5) 102.4 ± 23.4 (36.8–163.5) 71.4 ± 18.1 (33.4–111.3) < 0.001
aT4 level muscle index, cm2/m2 35.7 ± 8.5 (13.2–55.9) 37.2 ± 8.2 (13.2–55.9) 30.0 ± 7.5 (17.9–45.0) < 0.001
T12 Erector spinae muscle CSA, cm2 28.2 ± 9.1 (9.8–55.9) 29.4 ± 8.2 (13.2–55.9) 23.5 ± 7.5 (9.8–38.8) 0.001
bT12 muscle index, cm2/m2 10.5 ± 3.3 (3.8–23.2) 10.7 ± 3.3 (3.8–23.2) 9.9 ± 3.1 (4.5–15.8) 0.184
Follow-up time, months 37.9 ± 22.5 (0.1–91) 37.0 ± 21.9 (0.1–90.8) 41.3 ± 25.0 (0.4–91) 0.301
GAP Index score 3.3 ± 1.4 (0–7) 3.5 ± 1.4 (1–7) 2.8 ± 1.5 (0–6) 0.006
1-year survival, number, (%) 157 (87.2%) 124 (86.7%) 33 (89.2%) 0.688
2-year survival, number, (%) 138 (76.7%) 107 (74.8%) 31 (83.8%) 0.284
Continuous variables are presented as mean ± standard deviation (range) and categorical variables are presented as numbers (percentage)
Abbreviations: BMI Body Mass Index, FEV1 Forced Expiratory Volume, FVC Forced Vital Capacity, TLC Total Lung Capacity, DLCO diffusing capacity of carbon
monoxide, CSA Cross Sectional Area, GAP gender, age, and physiologic variables
aT4 level muscle index = CSA of pectoralis, intercostalis, paraspinals, serratus, and latissimus muscles at T4 level/height2
bT12 level muscle index = CSA of erector spinae muscle at T12 level/height2
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Results
Baseline characteristics
Baseline characteristics of the study subjects are pro-
vided in Table 1. The proportion of male patients was
79.4%. The mean age for all patients was 69.1 years
(range, 44–94 years); the mean ages of male and female
patients were 68.7 years (range, 44–89 years) and 70.0
years (range, 52–94 years), respectively.
Compared with female patients, male patients had
higher body mass indexes (BMI), a greater tendency to
be smokers, higher FVC, L, forced expiratory volume
(FEV1), L, and FEV1/FVC, DLCO, higher GAP index score,
higher T4CSA and ESMCSA, higher T4MI (37.2 cm
2/m2 vs.
30.0 cm2/m2, respectively, P < 0.001). FVC and FEV1
percentage of predicted value, and T12MI did not differ
significantly between male and female patients.
Of 143 male patients with IPF, 53 (37.1%) died during
the follow-up period. Respective 1-year survival and
2-year survival rates were 86.7 and 74.8%. Of 37 female
patients with IPF, 15 (40.5%) died during the follow-up
period. Respective 1-year survival and 2-year survival
rates were 89.2 and 83.8%. One-year (P = 0.688) and
two-year survival (P = 0.284) rates did not differ between
male and female patients.
Clinical characteristics and survival
We divided the patients into two groups according to
CSA divided by height square to visualize the effects of
lowest quartile CSA divided by height square. Male and
female patients were divided and analyzed separately as
male and female exhibited significant difference in
muscle mass. And there is no defined cutoff point for
defining sarcopenia in chest CT in T4 and T12 levels,
we divided the patients into four groups according to
T4MI and T12MI in male and female, respectively. And
lowest quartile of T4MI or T12MI groups was defined
as sarcopenia group.
When patients were stratified by T4CSA divided by
height square (T4MI) (n = 143); comparisons of clinical
characteristics and survival between the lowest quartile
of T4MI (sarcopenia) (Q4) and the rest (normal) group
(Q1 + 2 + 3) are shown in Table 2. The cutoff value
Table 2 Comparisons between Sarcopenia (lowest quartile of T4MI) (Q4) and the normal group (Q1 + Q2 + Q3) among men and
women, respectively
Variable Men(n = 143) Women(n = 37)
Normal (n = 107) Sarcopenia (n = 36) P-value Normal (n = 28) Sarcopenia (n = 9) P-value
Age, years 68.1 ± 7.9 70.8 ± 8.9 0.087 70.4 ± 8.2 71.6 ± 13.2 0.808
BMI, kg/m2 24.0 ± 3.1 23.3 ± 3.7 0.283 24.4 ± 3.1 22.7 ± 3.5 0.231
Ever smoker, % 92 (88.8%) 31 (86.1%) 0.336 3 (10.7%) 0 (0.0%) 0.592
Smoking history, pack-years 32.1 ± 23.9 29.7 ± 21.5 0.594 8.3 ± 7.6 0 n/a
Diabetes, n 36 (33.6%) 11 (30.6%) 0.839 8 (28.6%) 4 (44.4%) 0.432
Use of Statins or Sulfonylureas or Glinides, n 42 (39.3%) 11 (30.6%) 0.427 7 (25%) 6 (66.7%) 0.042
FVC, L 2.9 ± 0.7 2.62 ± 0.84 0.096 1.8 ± 0.5 1.7 ± 0.6 0.888
FVC, % predicted 78.9 ± 16.2 72.0 ± 18.9 0.040 73.8 ± 16.3 68.7 ± 18.1 0.516
FEV1, L 2.3 ± 0.6 2.14 ± 0.63 0.241 1.5 ± 0.4 1.5 ± 0.5 0.982
FEV1, % predicted 90.4 ± 18.0 86.1 ± 21.2 0.249 88.9 ± 17.8 85.3 ± 18.4 0.649
FEV1/FVC, % 79.8 ± 9.3 82.6 ± 8.1 0.117 84.6 ± 7.8 87.1 ± 6.6 0.409
DLCO, % predicted 73.7 ± 22.8 64.9 ± 23.9 0.065 59.8 ± 20.3 66.2 ± 22.6 0.551
T4 level muscle CSA, cm2 111.7 ± 17.4 74.7 ± 15.6 < 0.001 78.2 ± 14.8 50.3 ± 8.3 < 0.001
aT4 level muscle index, cm2/m2 40.6 ± 5.8 26.86 ± 5.01 < 0.001 33.0 ± 6.0 20.8 ± 2.0 < 0.001
T12 Erector spinae muscle CSA, cm2 31.8 ± 8.4 21.99 ± 7.46 < 0.001 26.0 ± 5.6 15.2 ± 5.8 < 0.001
bT12 muscle index, cm2/m2 11.6 ± 3.0 7.95 ± 2.85 < 0.001 11.0 ± 2.4 6.2 ± 2.2 < 0.001
Follow-up time, months 38.8 ± 21.0 31.6 ± 23.8 0.087 39.7 ± 21.6 46.2 ± 34.5 0.603
GAP Index score 3.3 ± 1.3 4.0 ± 1.6 0.012 2.7 ± 1.3 3.1 ± 2.1 0.610
1-year survival, number, (%) 96 (89.7%) 28 (77.8%) 0.068 26 (92.9%) 7 (77.8%) 0.205
2-year survival, number, (%) 86 (80.4%) 21 (58.3%) 0.008 25 (89.3%) 6 (66.7%) 0.109
Data are presented as number of patients (%) or mean ± standard deviation
Abbreviations: Q quartile, BMI Body Mass Index, FEV1 Forced Expiratory Volume, FVC Forced Vital Capacity, TLC Total Lung Capacity, DLCO diffusing capacity of
carbon monoxide, CSA Cross Sectional Area, GAP gender, age, and physiologic variables
Cutoff values for lower quartile in men and women are 32.53 cm2/m2 and 24.25 cm2/m2, respectively
aT4 level muscle index = CSA of pectoralis, intercostalis, paraspinals, serratus, and latissimus muscles at T4 level/height2
bT12 level muscle index = CSA of erector spinae muscle at T12 level/height2
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corresponds to the lowest quartile of T4MI (men: T4MI
= 32.53 cm2/m2; women: T4MI = 24.25 cm2/m2, respect-
ively). In male patients, Forced Vital Capacity (FVC)%
predicted was lower and GAP index score was higher in
the Sarcopenia group than in the normal group. Clinical
characteristics, such as BMI, age, and smoking history
did not differ between sarcopenia and normal groups.
Respective 1-year survival rates of the Sarcopenia group
and the normal group were 77.8 and 89.7% (P = 0.068).
Respective 2-year survival rates of the Sarcopenia group
and the normal group were 58.3 and 80.4% (P = 0.008).
In female patients, although not statistically significant,
the sarcopenia group showed a lower 2-year survival
rate than that of the normal group (89.3% vs 66.7%,
P = 0.109).
Kaplan-Meier survival curves stratified by the sarcope-
nia and the normal group in male and female patients
are shown in Fig. 3a. Male patients in the sarcopenia group
exhibited a significantly lower survival rate (P = 0.035) than
those of the normal group. There was no significant differ-
ence in survival between the sarcopenia and the normal
group (P = 0.831) in Kaplan-Meier survival curves among
female patients.
Furthermore, patients were stratified by the ESMCSA
divided by height square (T12MI) (n = 139); comparisons
of clinical characteristics and survival between the low-
est quartile of T12MI (Sarcopenia) (Q4) and the rest
(normal) group (Q1 + 2 + 3) are shown in Table 2. The
cutoff value corresponds to the lowest quartile of T12MI
(men: T12MI = 8.67 cm2/m2; women: 7.13 cm2/m2, re-
spectively). In male patients, patients with sarcopenia
exhibited lower survival although the difference was not
statistically significant in men (P = 0.058). Respective
1-year survival rates of the sarcopenia group and normal
groups were 82.8 and 89.4% (P = 0.305). Respective
2-year survival rates of the sarcopenia and normal
groups were 60.0 and 80.8% (P = 0.013). In female pa-
tients, although not statistically significant, the sarcope-
nia group showed lower a 2-year survival rate than that
of the normal group (92.3% vs 66.7%, P = 0.058).
Kaplan-Meier survival curves stratified by sarcopenia
group and normal group in male and female patients are
shown in Fig. 3b. Male patients in the sarcopenia group
exhibited a lower survival rate (P = 0.058) than that of the
normal group, although this was not statistically signifi-
cant. There was no significant difference in survival rates
between the normal and the sarcopenia groups (P = 0.660)
in Kaplan-Meier survival curves among female patients.
Cox proportional hazards analyses
The relationships between all-cause mortality and clin-
ical parameters, including T4MI and T12MI, were evalu-
ated with Cox proportional hazards analysis (Table 3).
Univariate analysis showed that lower BMI, lower FVC%
predicted value, lower FEV1% predicted value, lower
DLCO% predicted value, lower T4MI (HR, 0.965; 95% CI,
0.937–0.993; P = 0.015), lower T12MI (HR, 0.910; 95% CI,
0.841–0.984; P = 0.019), and a higher GAP index score
were significantly correlated with all-cause mortality.
Fig. 3 a Kaplan–Meier survival curves stratified by the cross-sectional
area of pectoralis, intercostalis, paraspinals, serratus, and latissimus
muscles at the T4 level in male and female patients . The cutoff
value corresponds to the lowest quantile of the cross-sectional area
of muscle at the T4 level/height2 (T4 muscle index, T4MI) (Male:
T4MI = 32.53 cm2/m2, n = 108/35 respectively / Female: T4MI = 24.25
cm2/m2, n = 28 / 9 respectively). b Kaplan–Meier survival curves
stratified by the cross-sectional area of the erector spinae muscles at
the T12 level in male and female patients. The cutoff value
corresponds to the lowest quantile of the cross-sectional area of
erector spinae muscle/height2 (T12 muscle index, T12MI). (Male:
T12MI = 8.67 cm2/m2, n = 104/35 respectively / Female: T12MI = 7.13
cm2/m2, n = 28 / 9 respectively)
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Multivariate Cox proportional hazards analyses were
performed to compare the contributions of these indices
(Table 4). Stepwise Cox proportional hazards analysis
demonstrated that lower BMI (HR, 0.885; 95% CI,
0.806–0.972; P = 0.010) and lower T4MI (HR, 0.955; 95%
CI, 0.913–0.998; P = 0.041) were risk factors for all-cause
mortality. Lower T12MI (HR, 0.980; 95% CI, 0.856–1.121;
P = 0.766) was not a significant risk factor for all-cause
mortality after multivariate analysis. Higher GAP index
score was a significant risk factor for all-cause mortality
(HR, 1.450; 95% CI, 1.169–1.760; P = 0.001).
Discussion
To our knowledge, this study is the first to demonstrate
that quantitatively analyzing muscles with chest CT can
be useful in predicting the prognosis in patients with
IPF. Our study showed that low T4MI is a risk factor for
all-cause mortality in IPF patients, along with established
and reported prognostic predictors.
There can be several reasons for the relationship
between low T4MI with poor survival. First, muscles
at the T4 level are involved with breathing; quantita-
tive differences could result in altered performance,
thus resulting in altered outcomes. Second, decreased
lung function and symptoms of dyspnea could be
reasons for reduced muscle mass. Reduced physical
activity due to decreased lung function and dyspnea,
is well-documented and this might result in reduced
muscle mass [19, 20]. However, it is unclear whether
lower muscle mass led to increased disease severity,
or whether increased disease severity led to lower
muscle mass. Further studies investigating this mech-
anism are thus required.
Measurement of T4CSA has several advantages, com-
pared with parameters described in other reports per-
taining to the skeletal muscles, [12] such as the psoas
[14] and mid-thigh muscles [21]. Psoas muscle CSA may
be affected by positions of upper extremities during
scanning. Notably, other skeletal muscles require add-
itional scans and X-ray exposure for analysis; however, a
patient may not be able to undergo another evaluation
of sarcopenia because of poor health. Without any add-
itional radiation exposure, CSA analysis through existing
chest CT scans provides an additional and important
objective index of disease severity and future prognosis
in patients with IPF.
In our study, Kaplan–Meier survival analysis for male
patients with IPF who exhibited lower T12MI values
Table 3 Clinical factors associated with all-cause mortality in men and women patients (univariate analysis)
Variable Total (n = 180) Men (n = 143) Women (n = 37)
HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value
Age, yr 1.033 (1.001–1.064) 0.037 1.012 (0.978–1.047) 0.507 1.098 (1.036–1.164) 0.002
Sex, Female 1.031 (0.581–1.831) 0.916
BMI, kg/m2 0.900 (0.833–0.971) 0.007 0.861 (0.789–0.938) 0.001 1.044 (0.895–1.219) 0.583
Smoking history, pack-years 1.004 (0.993–1.015) 0.488 1.005 (0.994–1.016) 0.406 0.757 (0.259–2.211) 0.610
Diabetes, n 1.495 (0.922–2.425) 0.103 1.275 (0.731–2.222) 0.392 2.521 (0.907–7.012) 0.076
Use of Statins or Sulfonylureas or Glinides, n 0.962 (0.588–1.576) 0.879 0.944 (0.538–1.655) 0.840 0.964 (0.341–2.725) 0.945)
FVC % predicted 0.958 (0.944–0.973) < 0.001 0.961 (0.945–0.977) < 0.001 0.943 (0.907–0.982) 0.004
FEV1, % predicted 0.973 (0.960–0.986) < 0.001 0.975 (0.961–0.989) 0.001 0.964 (0.932–0.996) 0.030
DLCO % predicted 0.972 (0.959–0.985) < 0.001 0.969 (0.955–0.984) < 0.001 0.975 (0.938–1.012) 0.183
TLC, % predicted 0.970 (0.950–0.990) 0.004 0.970 (0.950–0.990) 0.004 0.944 (0.882–1.009) 0.091
aT4 level muscle index, cm2/m2 0.965 (0.937–0.993) 0.015 0.958 (0.926–0.991) 0.013 0.972 (0.904–1.044) 0.433
bT12 level muscle index, cm2/m2 0.910 (0.841–0.984) 0.019 0.908 (0.831–0.992) 0.033 0.917 (0.772–1.089) 0.322
GAP Score 1.356 (1.137–1.619) 0.001 1.366 (1.112–1.678) 0.003 1.403 (0.977–2.014) 0.067
Data are presented as Hazard Ratios (95% Confidence Intervals)
Abbreviations: BMI Body Mass Index, FEV1 Forced Expiratory Volume, FVC Forced Vital Capacity, TLC Total Lung Capacity, DLCO diffusing capacity of carbon
monoxide, CSA Cross Sectional Area, GAP gender, age, and physiologic variables
aT4 level muscle index = CSA of pectoralis, intercostalis, paraspinals, serratus, and latissimus muscles at T4 level/height2
bT12 level muscle index = CSA of erector spinae muscle at T12 level/height2
Table 4 Clinical factors associated with all-cause mortality in
the entire cohort (multivariate analysis)
Variables HR 95% CI P value
BMI, kg/m2 0.885 0.806–0.972 0.010
Smoking history, pack-years 0.993 0.977–1.009 0.367
aT4 level muscle index, cm2/m2 0.955 0.913–0.998 0.041
bT12 level muscle index, cm2/m2 0.980 0.856–1.121 0.766
GAP Score 1.450 1.169–1.760 0.001
Data are presented as Hazard Ratios (95% Confidence Intervals)
Abbreviations: BMI Body Mass Index, GAP gender, age, and
physiologic variables
aT4 level muscle index = CSA of pectoralis, intercostalis, paraspinals, serratus,
and latissimus muscles at T4 level/height2
bT12 level muscle index = CSA of erector spinae muscle at T12 level/height2
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demonstrated a significantly lower 2-year survival rate;
however, it was not significant in multivariate Cox pro-
portional hazards analysis. In the CT-based evaluation of
sarcopenia, transverse skeletal muscle index at L3, which
includes ESM, correlates well with whole-body compos-
ition measurements performed with dual-energy X-ray
absorptiometry [22]. Similarly, there is possibility that
measuring ESM at the level of T12 could have clinical
significance if CSA of muscles involved in breathing are
included in the analysis of CSA at the level of T12, con-
sidering the proximity of L3. More studies are needed to
clarify the relationship between muscle CSA at the level
of T12 and outcomes in IPF patients.
Many individual clinical variables have been shown to
predict survival in IPF [23–25]. The effect of muscle
mass on IPF prognosis was unknown. However, several
studies [6, 14, 15] suggested that thoracic muscle CSA is
related to physical activity, quadriceps volume, and
health-related quality of life in other lung diseases, such
as lung transplantation, chronic obstructive lung disease,
and non-small-cell lung cancer. Similarly, Izawa et al.
suggested a relationship between respiratory muscle
strength and sarcopenia in elderly cardiac patients [26].
Muscle mass involved in respiratory diseases may be also
important for IPF patients; indeed, our results showed
that skeletal muscle mass evaluated using chest CT can
be a prognostic factor in IPF.
Our study has certain limitations. First, the study was
retrospective study and the sample size was small, from
a single center, and involved no replication cohort.
Only Korean population were included in this study.
This cut-off values cannot be used in other races or
population considering that the cutoff for sarcopenia
can differ among different races [27]. However, the val-
idity of reported prognostic factors, such as the GAP
score, was confirmed in this study population, which
supports the present findings. In fact, the variables
which were not statistically significant in the analysis of
female patients could have been influenced by the small
sample size. Second, a standard method for measuring
CSA of the thoracic muscles has not yet been estab-
lished. As reports regarding measurement of thoracic
muscles are currently undergoing publication, we be-
lieve that a standard method for measuring CSA of
thoracic muscles will soon be established. Third, the
physical activity levels of all subjects were not directly
evaluated. It is possible that there may be relationship
to physical inactivity and lower muscle mass. We could
not include data regarding physical function testing as
these were not available at the time of analysis. How-
ever, based on other reports, [4, 5, 13] we suspect that
skeletal muscles of the chest may reflect both physical
activity and physiological parameters. Further analysis
is needed to verify these assumptions.
Conclusions
In conclusion, low T4CSA, normalized for stature, ob-
tained from a single-slice axial chest CT image may be a
strong risk factor for all-cause mortality in patients with
IPF. Without additional radiation exposure, CSA analysis
via existing chest CT scans provides an important index
reflecting future prognosis in patients with IPF. This
might aid in selection of an optimal treatment and
enable early intervention to maintain muscle mass and
improve prognosis. Close observation is needed in IPF
patients with a lower skeletal muscle mass and early re-
ferral to lung transplantation program can be suggested
in these patients if they fulfill the criteria for lung trans-
plantation. Furthermore, referring to pulmonary rehabili-
tation can be beneficial in these patients. Additional
studies are required to determine optimum reference
values for predicting IPF-specific outcomes.
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